Jonathan Spicer
McGill University, Montreal, QC Canada · McGill University Health Centre/Research Institute of the McGill University Health Centre
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jonathan Spicer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:29 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05714891 · Neoadjuvant Platform Trial in Non-Small Cell Lung CancerCanadian Cancer Trials Group · active not recruiting · NSCLC · study chair
- N/ANCT05583916 · Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung SurgeryMcGill University Health Centre/Research Institute of the McGill University Health Centre · unknown · Lung Cancer, Surgery · principal investigator
- Ph2NCT04638582 · Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)McGill University Health Centre/Research Institute of the McGill University Health Centre · terminated · Lung Cancer, Nonsmall Cell · principal investigator
- Ph1NCT04409925 · DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)McGill University Health Centre/Research Institute of the McGill University Health Centre · completed · COVID-19 Infection · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:29 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.N Engl J Med · 20222,541 citationsRCR 184.1
- Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.N Engl J Med · 20231,104 citationsRCR 94.7
- Perioperative Nivolumab in Resectable Lung Cancer.N Engl J Med · 2024535 citationsRCR 59.3
- 320 citationsRCR 34.5
- Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.J Clin Oncol · 2010293 citationsRCR 6.4
- 245 citationsRCR 50.5
- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.Lancet Oncol · 2019210 citationsRCR 8.0
- Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.Cancer Discov · 2023131 citationsRCR 8.5
- 114 citationsRCR 3.4
- Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.J Clin Oncol · 201798 citationsRCR 3.0